Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

930 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TR, Anthoney A, Ranson M, Boddy AV, Plummer R. Jamieson D, et al. Among authors: dean e. Eur J Cancer. 2016 Nov;68:1-10. doi: 10.1016/j.ejca.2016.08.026. Epub 2016 Sep 28. Eur J Cancer. 2016. PMID: 27693888 Free article. Clinical Trial.
IAPs as a target for anticancer therapy.
Danson S, Dean E, Dive C, Ranson M. Danson S, et al. Among authors: dean e. Curr Cancer Drug Targets. 2007 Dec;7(8):785-94. doi: 10.2174/156800907783220471. Curr Cancer Drug Targets. 2007. PMID: 18220537 Review.
Biomarkers of apoptosis.
Ward TH, Cummings J, Dean E, Greystoke A, Hou JM, Backen A, Ranson M, Dive C. Ward TH, et al. Among authors: dean e. Br J Cancer. 2008 Sep 16;99(6):841-6. doi: 10.1038/sj.bjc.6604519. Br J Cancer. 2008. PMID: 19238626 Free PMC article. Review.
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin.
Ranson M, Shaw H, Wolf J, Hamilton M, McCarthy S, Dean E, Reid A, Judson I. Ranson M, et al. Among authors: dean e. Cancer Chemother Pharmacol. 2010 May;66(1):53-8. doi: 10.1007/s00280-009-1133-3. Epub 2009 Dec 3. Cancer Chemother Pharmacol. 2010. PMID: 19956953 Clinical Trial.
930 results